Form 4: Salarius Director Sells SLRX Shares Under 10b5-1 Plan

Salarius Pharmaceuticals Director Arnold C. Hanish sold a total of 27 common shares at $0.6397 per share on December 30, 2025, under a Rule 10b5-1 plan.

Summary

• Arnold C. Hanish, a Director of Salarius Pharmaceuticals, Inc. (SLRX), reported the sale of common stock.
• The transactions occurred on December 30, 2025.
• A total of 27 shares of common stock were disposed of at a price of $0.6397 per share.
• This includes 15 shares sold indirectly by the Arnold C. Hanish Trust and 12 shares sold directly by Arnold C. Hanish.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Arnold C. Hanish beneficially owns 5,000 shares indirectly through the Arnold C. Hanish Trust and 0 shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be seen as negative, the small number of shares sold (27 total) and the execution under a pre-arranged Rule 10b5-1 plan significantly mitigate any negative implications, suggesting a routine portfolio management action rather than a signal of lack of confidence.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on immediate material non-public information, which enhances transparency.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived as a neutral to slightly negative signal regarding management's confidence in the company's near-term prospects, though the small transaction size mitigates this.

Stakeholder Impact

• Shareholders: The sale of a very small number of shares by a director, even under a 10b5-1 plan, has a negligible direct impact on the company's valuation or share price. It provides transparency regarding insider holdings.

Key Dates

Keywords

Salarius Pharmaceuticals, SLRX, Form 4, Insider Trading, Director Sale, Common Stock, 10b5-1 Plan